| Idioma original | English |
|---|---|
| Páginas (desde-hasta) | 425-427 |
| Número de páginas | 3 |
| Publicación | Statistics in Biopharmaceutical Research |
| Volumen | 16 |
| N.º | 4 |
| DOI |
|
| Estado | Published - 2024 |
Financiación
The author(s) reported there is no funding associated with the work featured in this article. The authors thank the National Institute of Statistical Sciences for facilitating this work on Randomization Tests to Address Disruptions in Clinical Trials, which is part of the Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions. The authors would also like to recognize the organizers of this forum series (those who are not an author on this article): Nancy Flournoy and James Rosenberger. We thank Kaspar Rufibach for helpful discussions on the representativeness heuristic.
| Financiadores |
|---|
| National Institute of Statistical Sciences |
| Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions |
ASJC Scopus subject areas
- Statistics and Probability
- Pharmaceutical Science
Citar esto
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver